Content

The Webinar "Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma" Organized by Hepatoma Research Has Been Successfully Held

Published on: 8 Nov 2022 Viewed: 641

The webinar "Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma" organized by Hepatoma Research and chaired by Prof. Timothy M. Pawlik, from the Ohio State University Wexner Medical Center, Columbus, OH, USA, has been successfully held on November 2, 2022.

Six outstanding international Guest Speakers delivered excellent speeches and shared their novel insights on the treatment of intrahepatic cholangiocarcinoma (ICC).

Dr. Kimberly Washington comes from the Department of Surgery at Texas Christian University, USA. She gave a comprehensive presentation focusing on “Epidemiology, Risk Factors, and Disparities in ICC”.
Topic: Epidemiology & Incidence, Geographic Factors, and Risk Factors

Prof. Wen-Ming Cong, who is from the Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Shanghai, China, presented how to improve the fine pathological diagnosis of ICC through a brief introduction to Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma of China (2022 Edition).
Topic: Improve the Fine Pathological Diagnosis of Intrahepatic Cholangiocarcinoma: a brief introduction to Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma of China (2022 Edition)

Prof. Ihab Roushdy Kamel, who works in the Department of Radiology of Johns Hopkins University School of Medicine, MD, USA, talked about the radiologic imaging of ICC from four aspects: presentation/risk factors, classification, imaging findings, and response assessment.
Topic: Radiologic Imaging of ICC

Prof. Timothy M. Pawlik, the Chair of the webinar, also gave an informative talk on the topic “Surgical Management of ICC”. He mainly concluded that routine lymphadenectomy should be performed for local disease control and
ensure adequate staging of patients (i.e., beyond LN Station 12, 6 LNs), and a multi-modality and multi-disciplinary approach is needed to improve and increase the overall survival outcomes.
Topic: Surgical Therapy for ICC

Prof. Sameek Roychowdhury, from the Ohio State University Comprehensive Cancer Center, OH, USA, discussed the systemic therapies for advanced cholangiocarcinoma by introducing the types of cholangiocarcinoma, first-line therapies and trials (Gem/Cis/PD-1, Gem/Cis/Abraxane), and additional therapies (FGFR, IDH, BRAF, ERBBx, EGFR, NTRK, MSI-H).
Topic: Systemic Therapies for Advanced Cholangiocarcinoma

Prof. Bas Groot Koerkamp, who works at Erasmus University Medical Centre of Rotterdam in the Netherlands, talked about HAI therapy from two main aspects: unresectable ICC and intra-arterial chemo with floxuridine. Additionally, he summarized a flowchart of the treatment of ICC.
Topic: HAI Therapy for ICC

During the free discussion, Prof. Giuliano Ramadori, the Executive Chief Editor of Hepatoma Research, and the speakers had a lively discussion on some topics:

How should we think about the intrahepatic cholangiocarcinoma based on the epidemiology?

Could you please comment more on the CT or MRI for primary diagnosisof ICC?

What kind of biomarkers are used for diagnosis or treatment of ICC?

Could you comment on other local regional therapy if you think any role of Y-90 or SBRT in the treatment of ICC?

What's your opinion on tyrosine kinase inhibitor (TKI) in advanced ICC?

What's your thoughts about reducing futile resections in intrahepatic cholangiocarcinoma?

Do you have any comments on preoperative predictive factors (biological, radiological) or models to prevent such futile resections?

etc.

Discussion Part 1 & Discussion Part 2

The Editorial Office of Hepatoma Research thanks the Chair, Prof. Timothy M. Pawlik, for organizing this great webinar and appreciates all Guest Speakers’ substantial efforts to make this webinar a great success.

Finally, we call for papers for the Special Issue led by Prof. Timothy M. Pawlik, "Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma". Welcome to submit your manuscript at: https://oaemesas.com/login?JournalId=hr&SpecialIssueId=hr220928.

Welcome more researchers and scholars to join the journal’s future webinars! Stay tuned for more wonderful webinars of the journal: https://oaepublish.com/hr.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/